公开(公告)号：US20160187337A1

公开(公告)日：2016-06-30

申请号：US15063777

申请日：2016-03-08

Applicant: Biogen MA Inc.

Inventor： Leonid Gorelik ,  Kenneth J. Simon ,  Meena Subramanyam ,  Mia Marie Rushe

IPC: G01N33/569

CPC classification number: G01N33/56983 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/50

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

Abstract translation: 本公开涉及用于分析样品存在JC病毒抗体的方法和试剂。 公开了一种方法，其包括从适合于JCV抗体结合的条件下获得来自受试者（例如血浆，血清，血液，尿液或脑脊液）的生物样品，使样品与高度纯化的病毒样颗粒HPVLP接触） 在样品中检测HPVLP，并检测样品中JCV抗体与HPVLP结合的水平。在一个实施方案中，确定受试样品中抗JCV抗体的水平提供了在受试者中鉴定PML风险的方法。

公开(公告)号：US20220153874A1

公开(公告)日：2022-05-19

申请号：US17050353

申请日：2019-04-25

Applicant: Biogen MA Inc. ,  Neurimmune AG

Inventor： Jan Grimm ,  Fabio Montrasio ,  Isin Dalkilic-Liddle ,  Mia Marie Rushe ,  Joseph Walter Arndt

IPC: C07K16/44 ,  A61K49/00 ,  A61K47/68 ,  A61K51/10

Abstract: Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.

公开(公告)号：US10444234B2

公开(公告)日：2019-10-15

申请号：US15063777

申请日：2016-03-08

Applicant: Biogen MA Inc.

Inventor： Leonid Gorelik ,  Kenneth J. Simon ,  Meena Subramanyam ,  Mia Marie Rushe

IPC: C12Q1/70 ,  G01N33/569

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

公开(公告)号：US12162952B2

公开(公告)日：2024-12-10

申请号：US17050353

申请日：2019-04-25

Applicant: Biogen MA Inc. ,  Neurimmune AG

Inventor： Jan Grimm ,  Fabio Montrasio ,  Isin Dalkilic-Liddle ,  Mia Marie Rushe ,  Joseph Walter Arndt

IPC: C07K16/00 ,  A61K47/68 ,  A61K49/00 ,  A61K51/10 ,  C07K16/44 ,  G01N33/53

Abstract: Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.

公开(公告)号：US11287423B2

公开(公告)日：2022-03-29

申请号：US16594843

申请日：2019-10-07

Applicant: Biogen MA Inc.

Inventor： Leonid Gorelik ,  Kenneth J. Simon ,  Meena Subramanyam ,  Mia Marie Rushe

IPC: G01N33/543

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.